TABLE 2

The association of individual SNPs and combinations of SNPs with circulating triglyceride levels from a meta-analysis of four studies of nondiabetic individuals and the Go-DARTS type 2 diabetes case-control study

SNP/weighted allele scoreNearest gene*SNP(s) vs. triglycerides (continuous-traits meta-analysis)SNP(s) vs. triglycerides (type 2 diabetes case-control analysis)
Triglyceride z score per allele (95% CI)PHeterogeneity P (I2%)Triglyceride z score per allele (95% CI)P
rs2954029TRIB10.10 (0.07–0.13)‡6 × 10−120.19 (37.5)0.08 (0.05–0.12)‡4 × 10−7
rs714052MLXIPL0.15 (0.11–0.20)‡2 × 10−110.81 (0.0)0.13 (0.08–0.18)‡1 × 10−7
rs7557067APOB0.05 (0.02–0.09)‡0.0020.62 (0.0)0.07 (0.03–0.10)‡0.001
rs17216525NCAN, CLIP2, PBX40.11 (0.05–0.16)‡8 × 10−50.42 (0.0)0.04 (−0.02 to 0.10)‡0.16
rs10889353ANGPTL30.06 (0.03–0.09)‡2 × 10−40.36 (6.8)0.05 (0.01–0.08)‡0.008
rs7679PLTP0.05 (0.02–0.09)‡0.0050.41 (0.0)0.06 (0.01–0.10)‡0.008
rs7819412XKR6-AMAC1L20.03 (0.00–0.06)‡0.0430.82 (0.0)0.01 (−0.02 to 0.04)‡0.54
rs328LPL0.21 (0.16–0.26)‡4 × 10−170.38 (2.1)0.21 (0.16–0.27)‡2 × 10−15
rs3135506APOA50.24 (0.18–0.30)‡1 × 10−140.33 (13.0)0.17 (0.10–0.25)‡5 × 10−6
rs662799APOA50.25 (0.18–0.31)‡1 × 10−140.60 (0.0)0.17 (0.10–0.27)‡1 × 10−6
Allele score0.12 (0.10–0.13)§9 × 10−760.003 (78.6)0.09 (0.08–0.11)§2 × 10−41
Q2 vs. Q10.22 (0.15–0.28)||2 × 10−110.93 (0.0)0.17 (0.10–0.24)||4 × 10−6
Q3 vs. Q10.32 (0.26–0.39)||3 × 10−230.78 (0.0)0.29 (0.21–0.36)||5 × 10−15
Q4 vs. Q10.38 (0.32–0.45)||3 × 10−320.85 (0.0)0.33 (0.26–0.40)||5 × 10−19
Q5 vs. Q10.59 (0.52–0.65)||2 × 10−720.16 (41.3)0.43 (0.36–0.50)||4 × 10−31
  • Q = quintile of weighted allele score.

  • The sample size in the allele score vs. triglyceride association was 8,084 and 8,335 in meta-analyses of the four continuous-outcome studies and Go-DARTS type 2 diabetic case and control subjects, respectively. For quintiles of allele score versus triglyceride analyses, the sample sizes ranged from 3,222 to 3,240 in continuous-traits meta-analyses and 3,315 to 3,372 in Go-DARTS type 2 diabetic case and control subjects.

  • *Nearest gene information reported as in Kathiresan et al. (31), except for rs328, which is from Kathiresan et al. (34) and for rs3135506 and rs662799, which are from Pennacchio et al. (32).

  • †Results from the continuous-traits meta-analysis and type 2 diabetes case-control analysis are not independent. A subset of control subjects from the type 2 diabetes case-control study are used in the continuous-traits study (those with fasting glucose <7.0 mmol/L and fasting insulin, triglycerides, and 8 of the 10 SNPs available).

  • The effect sizes reported are ‡change in triglyceride z score per triglyceride-raising allele for individual SNPs,

  • §change in triglyceride z score per unit increase in weighted allele score, or

  • ||difference in triglyceride z score between the relevant quintiles of the weighted allele score.